PRNewswire (Thu, 29-Jan 7:00 AM ET)
PRNewswire (Mon, 12-Jan 7:00 AM ET)
PRNewswire (Mon, 5-Jan 7:00 AM ET)
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China
PRNewswire (Thu, 11-Dec 7:00 AM ET)
PRNewswire (Mon, 17-Nov 7:00 AM ET)
Market Chameleon (Mon, 3-Nov 3:50 AM ET)
NewcelX Ltd is a biotechnology company developing transformative cell-based and small-molecule therapies for neurodegenerative and metabolic diseases. The company's integrated platform combines advanced stem-cell technologies and neuroscience expertise to deliver scalable, regenerative treatments targeting conditions such as Amyotrophic Lateral Sclerosis (ALS) and Type 1 Diabetes. It has research and development operations in Ness Ziona, Israel.
Newcelx Ltd. - trades on the NASDAQ stock market under the symbol NCEL.
As of February 11, 2026, NCEL stock price declined to $2.76 with 13,478 million shares trading.
NCEL has a beta of 8.19, meaning it tends to be more sensitive to market movements. NCEL has a correlation of 0.36 to the broad based SPY ETF.
NCEL has a market cap of $12.58 million. This is considered a Sub-Micro Cap stock.
NCEL support price is $2.67 and resistance is $3.11 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that NCEL shares will trade within this expected range on the day.
